Enthesitis in psoriatic disease

Dermatology

Volumn 225, Issue 2, 2012, Pages 100-109

  McGonagle, Dennis G ^a   Helliwell, Philip ^b   Veale, Douglas ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Dublin Academic Medical Centre   (Ireland)

Author keywords

Enthesitis; Magnetic resonance imaging; Pathogenesis; Psoriatic arthritis; Tumour necrosis factor inhibitors; Ultrasound

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; MESALAZINE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; AUTOIMMUNITY; CLINICAL ASSESSMENT TOOL; CORTICOSTEROID THERAPY; DACTYLITIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECHOGRAPHY; EDEMA; ENTHESITIS; FIBROMYALGIA; GLADMAN INDEX; GLASGOW ULTRASOUND ENTHESITIS SCORING SYSTEM; HISTOPATHOLOGY; HUMAN; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; MAJOR ENTHESITIS INDEX; NAIL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; SPONDYLOARTHRITIS RESEARCH CONSORITUM OF CANADA ENTHESITIS INDEX; SYNOVITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ARTHRITIS, PSORIATIC; CLINICAL TRIALS AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX; TENDINOPATHY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870774959     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000341536     Document Type: Article

References (73)

1. Gladman DD, Antoni C, Mease P, et al: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(suppl 2):ii14-ii17. 2 Veale DJ: The epidemiology of psoriatic arthritis: fact or fiction? J Rheumatol 2000; 27: 1105-1106.
2. Zachariae H, Zachariae R, Blomqvist K, et al: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life study. Acta Derm Venereol 2002; 82: 108-113.
3. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D: Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005; 15: 279-283.
4. Reich K, Krüger K, Mösser R, Augustin M: Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1,511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047.
5. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
6. Chandran V, Schentag CT, Gladman DD: Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007; 57: 1560-1563.
7. Ibrahim G, Waxman R, Helliwell PS: The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-1378.
8. FitzGerald O, Winchester R: Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009; 11: 214.
9. Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
10. Husted JA, Gladman DD, Farewell VT, et al: Validating the SF-36 health survey questionnaire in patients with psoriatic psoriasis and psoriatic arthritis in the United States. J Rheumatol 1997; 24: 511-517.
11. Gladman DD: Psoriatic arthritis. Dermatol Ther 2009; 22: 40-55.
12. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990; 17: 809-812.
13. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I: A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003; 62: 68-70.
14. Ritchlin CT: Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006; 33: 1435-1438.
15. Cruzat V, Cuchacovich R, Espinoza LR: Undifferentiated spondyloarthritis: recent clinical and therapeutic advances. Curr Rheumatol Rep 2010; 12: 311-317.
16. Riente L, Delle Sedie A, Filippucci E, Iagnocco A, Meenagh G, Grassi W, Valesini G, Bombardieri S: Ultrasound imaging for the rheumatologist IX. Ultrasound imaging in spondyloarthritis. Clin Exp Rheumatol 2007; 25: 349-353.
17. Weger W: An update on the diagnosis and management of psoriatic arthritis. G Ital Dermatol Venereol 2011; 146: 1-8. 19 Healy PJ, Helliwell PS: Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008; 59: 686-691.
18. McQueen FM, Dalbeth N, Doyle A: MRI in psoriatic arthritis: insights into pathogenesis and treatment response. Curr Rheumatol Rep 2008; 10: 303-310.
19. Emad Y, Ragab Y, Bassyouni I, Moawayh O, Fawzy M, Saad A, Abou-Zeid A, Rasker JJ: Enthesitis and related changes in the knees in seronegative spondyloarthropathies and skin psoriasis: magnetic resonance imaging case-control study. J Rheumatol 2010; 37: 1709-1717.
20. Tan AL, McGonagle D: Psoriatic arthritis: correlation between imaging and pathology. Joint Bone Spine 2010; 77: 206-211.
21. McGonagle D, Conaghan PG, Emery P: Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.
22. Helliwell PS, Taylor WJ: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005; 64(suppl II):ii3-ii8.
23. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, Lubrano E, Krueger GG, van der Heijde D, Veale DJ, Kavanaugh A, Nash P, Ritchlin C, Taylor W, Strand V: Outcome measures in psoriatic arthritis. J Rheumatol 2007; 34: 1159-1166.
24. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J: Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34: 1167-1170.
25. Hanly JG, Russell ML, Gladman DD: Psoriatic spondyloarthropathy: a long-term prospective study. Ann Rheum Dis 1988; 47: 386-393.
26. Lehtinen A, Taavitsainen M, Leirisalo-Repo M: Sonographic analysis of enthesopathy in the lower extremities of patients with spondyloarthropathy. Clin Exp Rheumatol 1994; 2: 143-148.
27. Girolomoni G, Gisondi P: Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol Venereol 2009; 23(suppl 1):3-8.
28. Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM, Girolomoni G: Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis 2008; 67: 26-30.
29. Mease PJ, Antoni CE, Gladman DD, Taylor WJ: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64 (suppl 2):ii49-ii54.
30. Gladman DD, Landewé R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A: Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 2010; 37: 453-461.
31. McQueen F, Lassere M, Bird P, Haavardsholm EA, Peterfy C, Conaghan PG, Ejbjerg B, Genant H, O'Connor P, Emery P, Østergaard M: Developing a magnetic resonance imaging scoring system for peripheral psoriatic arthritis. J Rheumatol 2007; 34: 859-861.
32. Godfrin B, Zabraniecki L, Lamboley V, Bertrand-Latour F, Sans N, Fournié B: Spondyloarthropathy with entheseal pain. A prospective study in 33 patients. Joint Bone Spine 2004; 71: 557-562.
33. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394.
34. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick CW: Studies with an enthesitis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46: 197-202.
35. Balint PV, Kane D, Wilson H, McInnes IB, Sturrock RD: Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61: 905-910.
36. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van ver Tempel H, Mielants H, et al: Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62: 127-132.
37. Marzo-Ortega H, McGonagle D, Rhodes LA, Tan AL, Conaghan PG, O'Connor P, Tanner SF, Fraser A, Veale D, Emery P: Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007; 66: 778-781.
38. Gladman DD, Cook RJ, Schentag C, Feletar M, Inman RJ, Hitchon C, et al: The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the Spondyloarthritis Research Consortium of Canada. J Rheumatol 2004; 31: 1126-1131.
39. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
40. Maksymowych WP, Mallon C, Morrow S, et al: Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68: 948-953.
41. Coates LC, Helliwell PS. Disease measurement-enthesitis, skin, nails, spine and dactylitis. Best Pract Res Clin Rheumatol 2010; 24: 659-670.
42. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Militor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52: 1227-1236.
43. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A; IMPACT 2 Trial Investigators: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-1157.
44. Rahman P, Elder JT: Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012; 39: 431-433.
45. McGonagle D: Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol 2009; 23(suppl 1):9-13.
46. Tan AL, Toumi H, Benjamin M, Grainger AJ, Tanner SF, Emery P, McGonagle D: Combined high-resolution magnetic resonance imaging and histological examination to explore the role of ligaments and tendons in the phenotypic expression of early hand osteoarthritis. Ann Rheum Dis 2006; 65: 1267-1272.
47. Ash ZR, Tinazzi I, Gallego CC, et al: Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Ann Rheum Dis 2012; 71: 553-556.
48. Augustin M, Ogilvie A: Methods of outcomes measurement in nail psoriasis. Dermatology 2010; 221(suppl 1):23-28.
49. Aydin SZ, Ash Z, Del Galdo F, Marzo-Ortega H, Wakefield RJ, Emery P, McGonagle D: Optical coherence tomography: a new tool to assess nail disease in psoriasis? Dermatology 2011; 222: 311-313.
50. McGonagle D, Lories RJU, Tan AL, Benjamin M: The concept of a 'synovio-entheseal complex' and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482-2491.
51. Ibrahim G, Groves C, Chandramohan M, et al: Clinical and ultrasound examination of the Leeds Enthesitis Index in psoriatic arthritis. ISRN Rheumatol 2011; 2011: 731917.
52. Benjamin M, McGonagle D: Histopathologic changes at 'synovio-entheseal complexes' suggesting a novel mechanism for synovitis in osteoarthritis and spondylarthritis. Arthritis Rheum 2007; 56: 3601-3609.
53. Benjamin M, Toumi H, Suzuki D, Redman S, Emery P, McGonagle D: Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007; 56: 224-233.
54. McGonagle D, Tan AL, Benjamin M: The biomechanical link between skin and joint disease in psoriasis and psoriatic arthritis: what every dermatologist needs to know. Ann Rheum Dis 2008; 67: 1-4.
55. Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, Buggy D, Taylor CT, O'Sullivan J, Fearon U, Veale DJ: Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis 2010; 69: 1389-1395.
56. Kennedy A, Ng CT, Biniecka M, Saber T, Taylor C, O'Sullivan J, Veale DJ, Fearon U: Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum 2010; 62: 711-21.
57. Biniecka M, Fox E, Gao W, Ng CT, Veale DJ, Fearon U, O'Sullivan J: Hypoxia induces mitochondrial mutagenesis and dysfunction in inflammatory arthritis. Arthritis Rheum 2011; 63: 2172-2182.
58. Benjamin M, McGonagle D: The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009; 649: 57-70.
59. Ritchlin CT: Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2005; 17: 406-412.
60. Leung YY, Tam LS, Kun EW, et al: Psoriatic arthritis as a distinct disease entity. J Postgrad Med 2007; 53: 63-71.
61. McGonagle D, Tan AL, Benjamin M: The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009; 218: 97-102.
62. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, McGonagle D: The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis: a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-256.
63. Frenz C, Fritsch H, Hoch J: Plastination histologic investigations on the inserting pars terminalis aponeurosis dorsalis of three-sectioned fingers (in German). Ann Anat 2000; 182: 69-73.
64. McGonagle D, Benjamin M, Tan AL: The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 2009; 21: 340-347.
65. Armaka M, Apostolaki M, Jacques P, et al: Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205: 331-337.
66. Tinazzi I, McGonagle D, Biasi D, et al: Arthritis in patients with psoriasis: preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis. J Rheumatol 2011; 38: 2691-2692.
67. Kyle S, Chandler D, Griffiths CEM, Helliwell P, Lewis J, McInnes I, Oliver S, Symmons D, McHugh N, British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG): Guidelines for anti-TNF-therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 390-397.
68. Kumar N, Kay LJ, Walker DJ: The treatment of enthesitis in psoriatic arthritis. J Rheumatol 2004; 31: 2311-2312.
69. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C, IMPACT 2 Study Group: Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498-505.
70. Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I: A randomised, multicentre, double-blind placebocontrolled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010; 69: 1430-1435.
71. Gladman DD, Sampalis JS, Illouz O, Guérette B, ACCLAIM Study Investigators: Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010; 37: 1898-1906.
72. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A: Golimumab, a new human, tumor necrosis factor alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-986.
73. Rigopoulos D, Gregoriou S, Makris M, Ioannides D: Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 2011; 223: 325-329.